Journal: Current hematologic malignancy reports
This publication reviews advances in the management of polycythemia vera (PV), emphasizing the importance of targeting the underlying neoplastic clone driven by JAK2 mutations rather than solely controlling hematocrit levels and thrombotic risk.
Traditional therapies focus on symptom management and preventing thrombosis but do not adequately address disease progression.
Interferon-based treatments show promise by:
- Achieving complete hematologic responses
- Significantly reducing the JAK2V617F variant allele frequency (VAF)
- Correlating with durable molecular remission
- Improving event-free survival
- Reducing thrombotic events
The authors suggest a paradigm shift toward using molecular biomarkers to guide personalized therapy aimed at:
- Deep clonal depletion
- Disease modification
- Prevention of transformation to myelofibrosis or acute leukemia
Clonal molecular response emerges as a crucial biomarker for evaluating treatment efficacy and monitoring in clinical practice.